| Issue Date | Title | Author(s) |
| 2020-11 | An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line. | Sheikh, Z; Bradbury, P; Pozzoli, M; Young, PM; Ong, HX; Traini, D |
| 2016-10-01 | Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products | Pozzoli, M; Ong, HX; Morgan, L; Sukkar, M; Traini, D; Young, PM; Sonvico, F |
| 2015-06-01 | CHARACTERIZATION OF A COMMERCIAL NASAL POWDER DRUG DELIVERY DEVICE | Pozzoli, M; Sonvico, F; Zhu, B; Rogueda, P; Traini, D; Young, P |
| 2017-09-02 | Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery | Pozzoli, M; Traini, D; Young, PM; Sukkar, MB; Sonvico, F |
| 2016-10-02 | Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation | Pozzoli, M; Rogueda, P; Zhu, B; Smith, T; Young, PM; Traini, D; Sonvico, F |
| 2018-10-13 | Nanoemulsion-enabled oral delivery of novel anticancer ω-3 fatty acid derivatives | Pereira, GG; Rawling, T; Pozzoli, M; Pazderka, C; Chen, Y; Dunstan, CR; Murray, M; Sonvico, F |
| 2016-12-07 | The nasal delivery of nanoencapsulated statins – An approach for brain delivery | Clementino, A; Batger, M; Garrastazu, G; Pozzoli, M; Del Favero, E; Rondelli, V; Gutfilen, B; Barboza, T; Sukkar, MB; Souza, SAL; Cantù, L; Sonvico, F |
| 2015-01-01 | Opportunities and challenges for the nasal administration of nanoemulsions | Comfort, C; Garrastazu, G; Pozzoli, M; Sonvico, F |
| 2014-01 | Optimization of RPMI 2650 Cells as a Model for Nasal Mucosa | Pozzoli, M; Sonvico, F; Ong, HX; Traini, D; Bebawy, M; Young, P; Dalby, RN; Byron, PR; Peart, J; Suman, JD; Farr, SJ; Young, PM; Traini, D |
| 2016-11-16 | Resveratrol solid lipid microparticles as dry powder formulation for nasal delivery, characterization and in vitro deposition study | Martignoni, I; Trotta, V; Lee, WH; Loo, CY; Pozzoli, M; Young, PM; Scalia, S; Traini, D |
| 2021-07-05 | Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line. | Sheikh, Z; Bradbury, P; Reekie, TA; Pozzoli, M; Robinson, PD; Kassiou, M; Young, PM; Ong, HX; Traini, D |
